U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Description
Curator's Comment:: description was created based on several sources, including: https://www.drugs.com/mtm/cephradine.html | http://www.medicinenet.com/cephradine-oral/article.htm | https://www.ncbi.nlm.nih.gov/pubmed/4684646

Cephradine is a semisynthetic cephalosporin antibiotic. Cephradine is active against the following organisms in vitro: Group A beta-hemolytic streptococci; Staphylococci, including coagulase-positive, coagulase-negative, and penicillinase-producing strains; Streptococcus pneumoniae (formerly Diplococcus pneumoniae); Escherichia coli; Proteus mirabilis; Klebsiella species; Hemophilus influenza. It works by stopping the growth of bacteria. It is used to treat a wide variety of bacterial infections (e.g., skin, ear, respiratory and urinary tract infections). Pseudomembranous colitis has been reported in patients receiving cephradine both orally and intravenously. Diarrhea generally starts 1 to 16 days after starting cephradine therapy. Gastrointestinal side effects have included nausea, vomiting. Hypersensitivity reactions have included rash, urticaria, pruritus, and joint pain. Bacteriostats may interfere with the bactericidal action of cephalosporins in acute infection; other agents, e.g., aminoglycosides, colistin, polymyxins, vancomycin, may increase the possibility of nephrotoxicity.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
VELOSEF '125'

Approved Use

Cephradine is indicated in the treatment of the following infections: RESPIRATORY TRACT INFECTIONS (e.g., tonsillitis, pharyngitis, and lobar pneumonia) caused by group A beta-hemolytic streptococci and S. pneumoniae (formerly D. pneumonia). OTITIS MEDIA caused by group A beta-hemolytic streptococci, S. pneumoniae (formerly D. pneumoniae), H. influenzae, and staphylococci. SKIN AND SKIN STRUCTURE INFECTIONS caused by staphylococci (penicillin-susceptible and penicillin-resistant) and beta-hemolytic streptococci. URINARY TRACT INFECTIONS, including prostatitis, caused by E. coli, P. mirabilis, Klebsiella species, and enterococci (S. faecalis).

Launch Date

1.46102403E11
Curative
VELOSEF '125'

Approved Use

Cephradine is indicated in the treatment of the following infections: RESPIRATORY TRACT INFECTIONS (e.g., tonsillitis, pharyngitis, and lobar pneumonia) caused by group A beta-hemolytic streptococci and S. pneumoniae (formerly D. pneumonia). OTITIS MEDIA caused by group A beta-hemolytic streptococci, S. pneumoniae (formerly D. pneumoniae), H. influenzae, and staphylococci. SKIN AND SKIN STRUCTURE INFECTIONS caused by staphylococci (penicillin-susceptible and penicillin-resistant) and beta-hemolytic streptococci. URINARY TRACT INFECTIONS, including prostatitis, caused by E. coli, P. mirabilis, Klebsiella species, and enterococci (S. faecalis).

Launch Date

1.46102403E11
Curative
VELOSEF '125'

Approved Use

Cephradine is indicated in the treatment of the following infections: RESPIRATORY TRACT INFECTIONS (e.g., tonsillitis, pharyngitis, and lobar pneumonia) caused by group A beta-hemolytic streptococci and S. pneumoniae (formerly D. pneumonia). OTITIS MEDIA caused by group A beta-hemolytic streptococci, S. pneumoniae (formerly D. pneumoniae), H. influenzae, and staphylococci. SKIN AND SKIN STRUCTURE INFECTIONS caused by staphylococci (penicillin-susceptible and penicillin-resistant) and beta-hemolytic streptococci. URINARY TRACT INFECTIONS, including prostatitis, caused by E. coli, P. mirabilis, Klebsiella species, and enterococci (S. faecalis).

Launch Date

1.46102403E11
Curative
VELOSEF '125'

Approved Use

Cephradine is indicated in the treatment of the following infections: RESPIRATORY TRACT INFECTIONS (e.g., tonsillitis, pharyngitis, and lobar pneumonia) caused by group A beta-hemolytic streptococci and S. pneumoniae (formerly D. pneumonia). OTITIS MEDIA caused by group A beta-hemolytic streptococci, S. pneumoniae (formerly D. pneumoniae), H. influenzae, and staphylococci. SKIN AND SKIN STRUCTURE INFECTIONS caused by staphylococci (penicillin-susceptible and penicillin-resistant) and beta-hemolytic streptococci. URINARY TRACT INFECTIONS, including prostatitis, caused by E. coli, P. mirabilis, Klebsiella species, and enterococci (S. faecalis).

Launch Date

1.46102403E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
17.7 μg/mL
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CEPHRADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
27.5 μg × h/mL
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CEPHRADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.61 h
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CEPHRADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
PubMed

PubMed

TitleDatePubMed
Cutaneous vasculitis due to ciprofloxacin.
1992 Jul 4
Concentration-dependent preferences of absorptive and excretive transport cause atypical intestinal absorption of cyclic phenylalanylserine: small intestine acts as an interface between the body and ingested compounds.
2002
Effect of composition on the physicochemical properties and active substance release from gelatin-alginate sponge.
2003
Treatments for symptomatic urinary tract infections during pregnancy.
2003
Synthesis and antibacterial activity of cephradine metal complexes: part I complexes with magnesium, calcium, chromium and manganese.
2003 Jan
Concentration-dependent atypical intestinal absorption of cyclic phenylalanylserine: small intestine acts as an interface between the body and ingested compounds.
2003 Nov
Microbiology and drug sensitivity patterns of chronic suppurative otitis media.
2004 Aug
Preparation and characterization of porous hollow silica nanoparticles for drug delivery application.
2004 Feb
Molecularly imprinted solid phase extraction-pulsed elution-mass spectrometry for determination of cephalexin and alpha-aminocephalosporin antibiotics in human serum.
2004 Nov 15
Multicenter surveillance of antimicrobial resistance of Streptococcus pyogenes, Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis to 14 oral antibiotics.
2004 Sep
Re: "Methicillin-resistant Staphylococcus aureus in children with cystic fibrosis: an eradication protocol" Solis et al. (Pediatr Pulmonol 2003;36: 189-195).
2004 Sep
Nateglinide uptake by a ceftibuten transporter in the rat kidney brush-border membrane.
2005 Aug 30
Synthesis and antibacterial activity of cephradine metal complexes : part II complexes with cobalt, copper, zinc and cadmium.
2005 Jan
Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1.
2005 Jan
H+-dependent transport mechanism of nateglinide in the brush-border membrane of the rat intestine.
2005 Jan
Purification and characterization of inducible cephalexin synthesizing enzyme in Gluconobacter oxydans.
2005 Mar
Determination of ceftriaxone in cerebrospinal fluid by ion-pair liquid chromatography.
2005 Mar-Apr
Preparation and characterization of uniform nanosized cephradine by combination of reactive precipitation and liquid anti-solvent precipitation under high gravity environment.
2005 Sep 14
Properties and active substance release kinetics from gelatin-alginate matrices.
2006
[Bacterial pathogens and resistance patterns in community acquired pediatric urinary tract infection: experience of 152 cases].
2006 Apr
A case of inadvertent anterior chamber and corneal stromal injection with antibiotics during cataract operation.
2006 Dec
A specific and rapid HPLC assay for the determination of cefroxadine in human plasma and its application to pharmacokinetic study in Korean.
2006 Feb 13
Chemiluminescence flow-injection analysis of beta-lactam antibiotics using the luminol-permanganate reaction.
2006 Jul-Aug
Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters.
2007 Jul 15
Development of intestinal bifidobacteria and lactobacilli in breast-fed neonates.
2007 Oct
Quantitative prediction of oral absorption of PEPT1 substrates based on in vitro uptake into Caco-2 cells.
2008 Apr 16
A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine.
2008 Aug
Effects of treatment with antimicrobial agents on the human colonic microflora.
2008 Dec
Cranial osteomyelitis: a late complication of a dental infection.
2008 Dec
[Prophylactic use of antibiotics in selective colorectal operation: a randomized controlled trial].
2008 Jan 15
Aeromonas salmonicida peritonitis after eating fish in a patient undergoing CAPD.
2008 May-Jun
Pharmacokinetic study of cephradine in Pakistani healthy male volunteers.
2008 Oct
Kinetic spectrophotometric determination of certain cephalosporins in pharmaceutical formulations.
2009
Antibiotic susceptibility of thermo-tolerant Escherichia coli 2 isolated from drinking water of Khairpur City, Sindh, Pakistan.
2009 Apr 15
A study of the chemiluminescence behavior of cephalosporins with luminol and its analytical application.
2009 Aug
[Analysis of multiple cephalosporins in blood and urine by HPLC].
2009 Dec
[Kneading and dispersing manipulation in treatment of early-stage acute mastitis: a randomized controlled trial].
2009 Dec
Rapid and simple method for determination of cephradine in human plasma using liquid chromatography-tandem mass spectrometry (LC-MS/MS): application to the bioequivalence study.
2009 Dec 1
[Study of cefadroxil and cephradine charge transfer process by fluorescence quenching method].
2009 Feb
Antibiotic susceptibility pattern of Staphylococcus epidermidis.
2009 Jul
[Microcalorimetric investigation of two cephalosporins on colon bacteria activity].
2009 Oct
[Antibiotic consumption and antimicrobial susceptibility evolution in the Centro Hospitalario Pereira Rossell in methicillin resistant Staphylococcus aureus era].
2009 Oct
Traumatic optic neuropathy accompanying orbital grease gun injury.
2010 Apr
Colorimetric detection of cephradine in pharmaceutical formulations via fluorosurfactant-capped gold nanoparticles.
2010 Apr 15
Avian colibacillosis and salmonellosis: a closer look at epidemiology, pathogenesis, diagnosis, control and public health concerns.
2010 Jan
Selective densitometric determination of four alpha-aminocephalosporins using ninhydrin reagent.
2010 Jan
A survey of the management of urinary tract infection in children in primary care and comparison with the NICE guidelines.
2010 Jan 26
Uropathogen resistance to antibiotic prophylaxis in urinary tract infections.
2010 Jun
Rate of conversion and complications of laparoscopic cholecystectomy in a tertiary care center in Saudi Arabia.
2010 Mar-Apr
Rhinoscleroma: case report.
2010 Sep-Oct
Patents

Sample Use Guides

For respiratory tract infections (other than lobar pneumonia) and skin and skin structure infections, the usual dose is 250 mg every 6 hours or 500 mg every 12 hours. For lobar pneumonia, the usual dose is 500 mg every 6 hours or 1 g every 12 hours. For uncomplicated urinary tract infections, the usual dose is 500 mg every 12 hours. In more serious urinary tract infections, including prostatitis, 500 mg every 6 hours or 1 g every 12 hours may be administered. Larger doses (up to 1 g every 6 hours) may be given for severe or chronic infections.
Route of Administration: Oral
In Vitro Use Guide
Sources: DOI: 10.5897/IJPS11.057
MIC 90 of Cephradine standard powder against 25 clinical isolates of S. aureus was 2048 ug/ml.
Substance Class Mixture
Created
by admin
on Fri Jun 25 20:52:02 UTC 2021
Edited
by admin
on Fri Jun 25 20:52:02 UTC 2021
Record UNII
F1BC02I72W
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CEPHRADINE
ORANGE BOOK   USAN   USP   VANDF  
USAN  
Official Name English
VELOSEF
Brand Name English
CEPHRADINE HYDRATE [MART.]
Common Name English
CEPHRADINE [USP-RS]
Common Name English
CEFRADINE HYDRATE
Common Name English
CEPHRADINE [VANDF]
Common Name English
SK&F-D-39304
Code English
SQ-11436
Code English
SQ-22022
Code English
CEPHRADINE [USP MONOGRAPH]
Common Name English
ANSPOR
Brand Name English
5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID, 7-(2-AMINO-2-(1,4-CYCLOHEXADIEN-1-YL)ACETAMIDO)-3-METHYL-8-OXO-, HYDRATE, D-
Common Name English
CEPHRADINE NON-STOICHIOMETRIC HYDRATE FORM
Common Name English
SQ 11436
Code English
CEPHRADINE, UNSPECIFIED HYDRATE
Common Name English
CEPHRADINE [ORANGE BOOK]
Common Name English
CEPHRADINE [USAN]
Common Name English
CEPHRADINE HYDRATE
MART.  
Common Name English
SK&F D-39304
Code English
Classification Tree Code System Code
WHO-ATC J01DB09
Created by admin on Fri Jun 25 20:52:02 UTC 2021 , Edited by admin on Fri Jun 25 20:52:02 UTC 2021
NCI_THESAURUS C357
Created by admin on Fri Jun 25 20:52:02 UTC 2021 , Edited by admin on Fri Jun 25 20:52:02 UTC 2021
LIVERTOX 178
Created by admin on Fri Jun 25 20:52:02 UTC 2021 , Edited by admin on Fri Jun 25 20:52:02 UTC 2021
NDF-RT N0000175488
Created by admin on Fri Jun 25 20:52:02 UTC 2021 , Edited by admin on Fri Jun 25 20:52:02 UTC 2021
Code System Code Type Description
NCI_THESAURUS
C47441
Created by admin on Fri Jun 25 20:52:02 UTC 2021 , Edited by admin on Fri Jun 25 20:52:02 UTC 2021
PRIMARY
EVMPD
SUB21808
Created by admin on Fri Jun 25 20:52:02 UTC 2021 , Edited by admin on Fri Jun 25 20:52:02 UTC 2021
PRIMARY
MESH
D002515
Created by admin on Fri Jun 25 20:52:02 UTC 2021 , Edited by admin on Fri Jun 25 20:52:02 UTC 2021
PRIMARY
ChEMBL
CHEMBL1604
Created by admin on Fri Jun 25 20:52:02 UTC 2021 , Edited by admin on Fri Jun 25 20:52:02 UTC 2021
PRIMARY
FDA UNII
F1BC02I72W
Created by admin on Fri Jun 25 20:52:02 UTC 2021 , Edited by admin on Fri Jun 25 20:52:02 UTC 2021
PRIMARY
USP_CATALOG
1102805
Created by admin on Fri Jun 25 20:52:02 UTC 2021 , Edited by admin on Fri Jun 25 20:52:02 UTC 2021
PRIMARY USP-RS
EVMPD
SUB07417MIG
Created by admin on Fri Jun 25 20:52:02 UTC 2021 , Edited by admin on Fri Jun 25 20:52:02 UTC 2021
PRIMARY
IUPHAR
4830
Created by admin on Fri Jun 25 20:52:02 UTC 2021 , Edited by admin on Fri Jun 25 20:52:02 UTC 2021
PRIMARY
RXCUI
2239
Created by admin on Fri Jun 25 20:52:02 UTC 2021 , Edited by admin on Fri Jun 25 20:52:02 UTC 2021
PRIMARY RxNorm
LACTMED
Cephradine
Created by admin on Fri Jun 25 20:52:02 UTC 2021 , Edited by admin on Fri Jun 25 20:52:02 UTC 2021
PRIMARY
Related Record Type Details
TRANSPORTER -> SUBSTRATE
TRANSPORTER -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Definition References